Plasma N-glycans in colorectal cancer risk.

Autor: Doherty M; National Institute for Bioprocessing Research & Training, Dublin, Ireland. Doherty.Margaret@itsligo.ie.; Institute of Technology Sligo, Department of Life Sciences, Sligo, Ireland. Doherty.Margaret@itsligo.ie., Theodoratou E; Centre for Global Health Research, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council Human Genetics Unit, Edinburgh, UK., Walsh I; Bioprocessing Technology Institute, Agency for Science, Technology and Research (A*STAR), 20 Biopolis Way, #06-01 Centros, Singapore, 138668, Singapore., Adamczyk B; National Institute for Bioprocessing Research & Training, Dublin, Ireland.; Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Stöckmann H; National Institute for Bioprocessing Research & Training, Dublin, Ireland., Agakov F; Pharmatics Limited, Edinburgh Bioquarter, 9 Little France Road, Edinburgh, UK., Timofeeva M; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council Human Genetics Unit, Edinburgh, UK., Trbojević-Akmačić I; Genos Glycoscience Research Laboratory, Zagreb, Croatia., Vučković F; Genos Glycoscience Research Laboratory, Zagreb, Croatia., Duffy F; National Institute for Bioprocessing Research & Training, Dublin, Ireland., McManus CA; National Institute for Bioprocessing Research & Training, Dublin, Ireland., Farrington SM; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council Human Genetics Unit, Edinburgh, UK., Dunlop MG; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council Human Genetics Unit, Edinburgh, UK., Perola M; Department of Health, The National Institute for Health and Welfare, Helsinki, Finland., Lauc G; Genos Glycoscience Research Laboratory, Zagreb, Croatia.; University of Zagreb Faculty of Pharmacy and Biochemistry, Zagreb, Croatia., Campbell H; Centre for Global Health Research, Usher Institute for Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council Human Genetics Unit, Edinburgh, UK., Rudd PM; National Institute for Bioprocessing Research & Training, Dublin, Ireland.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2018 Jun 05; Vol. 8 (1), pp. 8655. Date of Electronic Publication: 2018 Jun 05.
DOI: 10.1038/s41598-018-26805-7
Abstrakt: Aberrant glycosylation has been associated with a number of diseases including cancer. Our aim was to elucidate changes in whole plasma N-glycosylation between colorectal cancer (CRC) cases and controls in one of the largest cohorts of its kind. A set of 633 CRC patients and 478 age and gender matched controls was analysed. Additionally, patients were stratified into four CRC stages. Moreover, N-glycan analysis was carried out in plasma of 40 patients collected prior to the initial diagnosis of CRC. Statistically significant differences were observed in the plasma N-glycome at all stages of CRC, this included a highly significant decrease in relation to the core fucosylated bi-antennary glycans F(6)A2G2 and F(6)A2G2S(6)1 (P < 0.0009). Stage 1 showed a unique biomarker signature compared to stages 2, 3 and 4. There were indications that at risk groups could be identified from the glycome (retrospective AUC = 0.77 and prospective AUC = 0.65). N-glycome biomarkers related to the pathogenic progress of the disease would be a considerable asset in a clinical setting and it could enable novel therapeutics to be developed to target the disease in patients at risk of progression.
Databáze: MEDLINE
Externí odkaz: